Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 30 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Follow-Up Questions
Qui est le CEO de Zura Bio Ltd ?
Mr. Robert Lisicki est le Chief Executive Officer de Zura Bio Ltd, il a rejoint l'entreprise depuis 2024.
Quelle est la performance du prix de l'action ZURA ?
Le prix actuel de ZURA est de $3.37, il a increased de 0.14% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Zura Bio Ltd ?
Zura Bio Ltd appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Zura Bio Ltd ?
La capitalisation boursière actuelle de Zura Bio Ltd est de $219.4M
Est-ce que Zura Bio Ltd est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour Zura Bio Ltd, y compris 5 achat fort, 6 achat, 2 maintien, 0 vente et 5 vente forte
